In vivo CRISPR screen identifies gene edits that strengthen CAR-T therapy against solid tumors

AI Summary

Researchers identified gene edits using an in vivo CRISPR screen that enhance CAR-T cell therapy effectiveness against solid tumors such as lung and breast cancer. This advancement may improve immunotherapy treatments currently limited by resistance in solid tumor types.

For patients with blood cancers like leukemia and lymphoma, the immunotherapy known as CAR-T cell therapy can be lifesaving. Doctors remove a patient's immune cells, called T cells, engineer them in the lab to better recognize and attack cancer, and infuse them back into the bloodstream. But for solid tumors—which include lung, pancreatic, ovarian, colon, breast and other cancer types—these engineered immune cells still face too much resistance to effectively treat the disease.